The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.

 

Executive Summary and Global Market Analysis

Fueled by the growing number of breast and lung cancer cases and substantial investments in R&D, the global market for cancer therapeutics is expanding. The goal of these diverse treatments—from chemotherapy and radiation therapy to immunotherapy and targeted and hormone therapies—is to combat cancer, ease a patient's symptoms, and improve their quality of life and survival. A patient’s journey often involves a combination of these therapies, with treatment plans meticulously personalized to their specific type and stage of cancer, as well as their overall health.

 

Cancer Therapeutics Market Segmentation Analysis

The cancer therapeutics market is segmented in three key ways to understand its structure. First, by therapy type, the market is divided into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other approaches. Chemotherapy held the largest market share in 2024, demonstrating its foundational role in treatment. Second, by indication, the market addresses a range of cancers, including blood, lung, breast, and colorectal. Lung cancer represented the largest share of the market in 2024, highlighting its significant treatment burden. Finally, the market is segmented by distribution channel—hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies maintained the largest share of the market in 2024, showing where most patients receive their treatments.

 

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00031299

 

Cancer Therapeutics Market Drivers and Opportunities

A major driver for this market is the sheer number of people worldwide facing a cancer diagnosis. The World Health Organization reports that cancer is responsible for approximately one in six global deaths. The challenge is growing: an estimated 20 million new diagnoses in 2022 are projected to increase by a staggering 77% by 2050, which will place a significant burden on global healthcare systems. The American Cancer Society also highlights the genetic component of cancer, noting that 5–10% of all cancers are inherited. Mutations in genes like BRCA1 and BRCA2 significantly increase a person’s risk of developing cancers, including breast, ovarian, and prostate. Globally, breast cancer remains the most prevalent cancer among women, with its incidence continuously rising due to factors like environmental exposure, genetic susceptibility, and changing lifestyles.

 

Cancer Therapeutics Market Size and Share Analysis

When we look at the market’s size by therapy type, the chemotherapy segment held the dominant position in 2024. This is a foundational treatment, with its cytotoxic agents working to halt or slow the growth of cancer cells throughout the body via the bloodstream. This approach is widely used, with the National Institutes of Health estimating that roughly 650,000 cancer patients in the US undergo chemotherapy treatment annually. In terms of indications, the lung cancer segment commanded the largest share of the market in 2024, underscoring its significant market presence.

 

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications